Company News-royal proclamation
 
2nd Annual Spine Technology Awards
Pearl Diver
Procedure of the Month tools

Take the Multiple Choice Test Which choice best describes the patient's treatment options?

xray-spinal fusion
Sponsored by...
US Spine
Source: Tornier, Inc.

Tornier Wants to “Go Public”
Robin Young • Sun, Jun 20th, 2010

 

Tornier, the leading supplier of shoulder implants, has formally declared its intention to “go public.” Leaping into the public markets these days is not unlike deciding to swim in shark infested waters. The waters may look appealing, but it's not for the faint of heart.

Photo manipulation by RRY Publications. Source: Wikimedia Commons

DePuy’s State of the Union
Walter Eisner • Mon, Jun 14th, 2010

 

Johnson & Johnson conducted its bi-annual device meeting with analysts on June 3. What’s new for the DePuy franchise? Products, strategies and, surprisingly, a self described “opportunity” for the company in a tougher regulatory environment. Read what Mike Mahoney, DePuy’s happy warrior had to say.

Child with x-ray

The Growing Up of SAS
Walter Eisner • Tue, May 11th, 2010

 

The last two SAS meetings suffered from declining attendance and questions abound about the future of the Society. Former NASS president and newly elected SAS President Tom Errico, M.D., makes a spirited case for an international society for spine surgeons. Is SAS growing up or down? According to Errico…the answer is both.

Ribbon Cutting / Zimmer Holdings, Inc.

Zimmer Opens Trabecular Training Gem in NJ
Jacqueline Rupp • Mon, May 10th, 2010

 

Zimmer’s bet on Trabecular Metal took a major step forward with the opening of a state-of-the-art training center for orthopedic surgeons and dentists in Parsipanny, New Jersey. This is Zimmer's first OWI (Outside Warsaw Indiana) training facility and it was mighty impressive.

Image created by RRY Publications/Source: Regenexx, FDA

Regenexx: Recipe for Controversy?
Jacqueline Rupp • Tue, May 4th, 2010

 

The Centeno-Schultz Clinic's Regenexx stem cell therapy is being marketed as a treatment for several orthopedic indications. What’s the FDA’s take? The answer will surprise.

Crossroads / Wikimedia Commons

Why Baxter Paid $330 Million for ApaTech
Robin Young • Mon, Mar 29th, 2010

 

Certain acquisitions have the power to change an industry’s trajectory or focus. Looking back in five years, Baxter’s purchase of ApaTech for $330 million may well be ranked along with Danek’s merger with Sofamor, Sulzer’s purchase of Spine-Tech and Synthes acquisition of Spine Solutions as a bellwether deal.

IED Simulation / Creative Commons

Carpal Tunnel to IEDs
Jacqueline Rupp • Tue, Mar 23rd, 2010

 

How one simple device is offering diagnostic promise and stirring up debate about diagnostic technique and setting new guidelines for everything from repetitive stress syndromes to traumatic brain injuries.